These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 29874151)
21. Paclitaxel-loaded redox-sensitive nanoparticles based on hyaluronic acid-vitamin E succinate conjugates for improved lung cancer treatment. Song Y; Cai H; Yin T; Huo M; Ma P; Zhou J; Lai W Int J Nanomedicine; 2018; 13():1585-1600. PubMed ID: 29588586 [TBL] [Abstract][Full Text] [Related]
22. DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291. Li YL; Ding K; Hu X; Wu LW; Zhou DM; Rao MJ; Lin NM; Zhang C J Cell Mol Med; 2019 Nov; 23(11):7427-7437. PubMed ID: 31454149 [TBL] [Abstract][Full Text] [Related]
23. Development of paclitaxel loaded pegylated gelatin targeted nanoparticles for improved treatment efficacy in non-small cell lung cancer (NSCLC): an in vitro and in vivo evaluation study. Gu M; Luan J; Song K; Qiu C; Zhang X; Zhang M Acta Biochim Pol; 2021 Aug; 68(4):583-591. PubMed ID: 34355554 [TBL] [Abstract][Full Text] [Related]
24. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo. Wang W; Xi M; Duan X; Wang Y; Kong F Int J Nanomedicine; 2015; 10():3737-50. PubMed ID: 26045664 [TBL] [Abstract][Full Text] [Related]
25. AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells. Zhang Z; Zhang M; Liu H; Yin W J Cell Biochem; 2019 Jan; 120(1):756-767. PubMed ID: 30145802 [TBL] [Abstract][Full Text] [Related]
26. Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291 in H1975 cells. Liu Z; Gao W Arch Toxicol; 2020 Sep; 94(9):3125-3136. PubMed ID: 32577785 [TBL] [Abstract][Full Text] [Related]
27. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Eberlein CA; Stetson D; Markovets AA; Al-Kadhimi KJ; Lai Z; Fisher PR; Meador CB; Spitzler P; Ichihara E; Ross SJ; Ahdesmaki MJ; Ahmed A; Ratcliffe LE; O'Brien EL; Barnes CH; Brown H; Smith PD; Dry JR; Beran G; Thress KS; Dougherty B; Pao W; Cross DA Cancer Res; 2015 Jun; 75(12):2489-500. PubMed ID: 25870145 [TBL] [Abstract][Full Text] [Related]
28. MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers. Gu J; Yao W; Shi P; Zhang G; Owonikoko TK; Ramalingam SS; Sun SY Cancer; 2020 Aug; 126(16):3788-3799. PubMed ID: 32497272 [TBL] [Abstract][Full Text] [Related]
30. IGFBP7 overexpression promotes acquired resistance to AZD9291 in non-small cell lung cancer. Tang X; Mu J; Ma L; Tan Q; Wang J; Tan J; Zhang S Biochem Biophys Res Commun; 2021 Sep; 571():38-45. PubMed ID: 34303194 [TBL] [Abstract][Full Text] [Related]
31. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Planchard D; Loriot Y; André F; Gobert A; Auger N; Lacroix L; Soria JC Ann Oncol; 2015 Oct; 26(10):2073-8. PubMed ID: 26269204 [TBL] [Abstract][Full Text] [Related]
32. The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer. An B; Pan T; Hu J; Pang Y; Huang L; Chan ASC; Li X; Yan J Eur J Med Chem; 2019 Dec; 183():111709. PubMed ID: 31581004 [TBL] [Abstract][Full Text] [Related]
33. Discovery of highly potent and selective EGFR Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818 [TBL] [Abstract][Full Text] [Related]
34. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer. He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524 [TBL] [Abstract][Full Text] [Related]
35. Systemic delivery of micelles loading with paclitaxel using N-succinyl-palmitoyl-chitosan decorated with cRGDyK peptide to inhibit non-small-cell lung cancer. Yuan ZQ; Li JZ; Liu Y; Chen WL; Yang SD; Zhang CG; Zhu WJ; Zhou XF; Liu C; Zhang XN Int J Pharm; 2015 Aug; 492(1-2):141-51. PubMed ID: 26188316 [TBL] [Abstract][Full Text] [Related]
36. Identification of osimertinib (AZD9291) as a lysine specific demethylase 1 inhibitor. Li ZR; Suo FZ; Hu B; Guo YJ; Fu DJ; Yu B; Zheng YC; Liu HM Bioorg Chem; 2019 Mar; 84():164-169. PubMed ID: 30502627 [TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFR Zhao B; Xiao Z; Qi J; Luo R; Lan Z; Zhang Y; Hu X; Tang Q; Zheng P; Xu S; Zhu W Eur J Med Chem; 2019 Feb; 163():367-380. PubMed ID: 30530173 [TBL] [Abstract][Full Text] [Related]
38. Encapsulated paclitaxel nanoparticles exhibit enhanced anti-tumor efficacy in A549 non-small lung cancer cells. Huang G; Zang B; Wang X; Liu G; Zhao J Acta Biochim Biophys Sin (Shanghai); 2015 Dec; 47(12):981-7. PubMed ID: 26525950 [TBL] [Abstract][Full Text] [Related]
39. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670 [TBL] [Abstract][Full Text] [Related]
40. Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer. Gupta B; Poudel BK; Regmi S; Pathak S; Ruttala HB; Gautam M; An GJ; Jeong JH; Choi HG; Yong CS; Kim JO Pharm Res; 2018 Mar; 35(5):96. PubMed ID: 29536182 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]